Drugs Details

Drugs Info of Carac, Efudex, Efudex Occlusion Pack, Fluoroplex
Drugs Details
  • Drugs Type  : Multum
  • Date : 4th Feb 2015 03:05 am
  • Brand Name : Carac, Efudex, Efudex Occlusion Pack, Fluoroplex
  • Generic Name : fluorouracil topical (Pronunciation: flore oh YER a sill)
Descriptions

Carac® (fluorouracil cream) Cream, 0.5% , contains fluorouracil for topical dermatologic use. Chemically, fluorouracil is 5-fluoro-2,4(1H, 3H)-pyrimidinedione. The molecular formula is C4H3FN2O2. Fluorouracil has a molecular weight of 130.08.

 

Carac® (fluorouracil)  Structural Formula Illustration

Carac Cream contains 0.5% fluorouracil, with 0.35% being incorporated into a patented porous microsphere (Microsponge®)↑ composed of methyl methacrylate / glycol dimethacrylate cross polymer and dimethicone. The cream formulation contains the following other inactive ingredients: carbomer 940, dimethicone, glycerin, methyl gluceth-20, methyl methacrylate / glycol dimethacrylate crosspolymer, methylparaben, octyl hydroxy stearate, polyethylene glycol 400, polysorbate 80, propylene glycol, propylparaben, purified water, sorbitan monooleate, stearic acid, and trolamine.

What are the possible side effects of fluorouracil topical (Carac, Efudex, Efudex Occlusion Pack, Fluoroplex)?

Serious side effects are not likely to occur. Stop using fluorouracil topical and seek emergency medical attention if you experience an allergic reaction (shortness of breath; closing of your throat; swelling of your lips, face, or tongue; or hives).

Fluorouracil topical may cause skin irritation, dryness, scaling or peeling (exfoliation), rash, and other local reactions. Eye irritation has also been reported. If these side effects are excessive or worsen with continued treatment, contact your doctor.

Side effects other than those...

Read All Potential Side Effects and See Pictures of Carac »

This monograph has been modified to include the generic and brand name in many instances.

Indications

Carac (fluorouracil) is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp.

Dosage Administration

Carac (fluorouracil) cream should be applied once a day to the skin where actinic keratosis lesions appear, using enough to cover the entire area with a thin film. Carac (fluorouracil) cream should not be applied near the eyes, nostrils or mouth. Carac (fluorouracil) cream should be applied ten minutes after thoroughly washing, rinsing, and drying the entire area. Carac (fluorouracil) cream may be applied using the fingertips. Immediately after application, the hands should be thoroughly washed. Carac (fluorouracil) should be applied up to 4 weeks as tolerated. Continued treatment up to 4 weeks results in greater lesion reduction. Local irritation is not markedly increased by extending treatment from 2 to 4 weeks, and is generally resolved within 2 weeks of cessation of treatment.

How Supplied

Cream - 30 gram tube NDC 0066-7150-30

Store at Controlled Room Temperature 20 to 25°C (68 to 77°F) [see USP]. Prescribing Information as of 2006.

Keep out of the reach of children.

Dermik Laboratories, a business of sanofi-aventis U.S. LLC, Bridgewater, NJ 08807. FDA rev date: 12/16/2003

This monograph has been modified to include the generic and brand name in many instances.

Side Effects

The following were adverse events considered to be drug-related and occurring with a frequency of ≥ 1% with Carac (fluorouracil) : application site reaction (94.6%), and eye irritation (5.4%). The signs and symptoms of facial irritation (application site reaction) are presented below.

Summary of Facial Irritation Signs and Symptoms - Pooled Phase 3 Studies

Clinical Sign or
Symptom
Active One
Week
Active Two
Week
Active Four
Week
ALL Active
Treatments
Vehicle
Treatments
N=85 N=87 N=85 N=257 N=127
n (%) n (%) n (%) n (%) n (%)
Erythema 76 (89.4) 82 (94.3) 82 (96.5) 240 (93.4) 76 (59.8)
Dryness 59 (69.4) 76 (87.4) 79 (92.9) 214 (83.3) 60 (47.2)
Burning 51 (60.0) 70 (80.5) 71 (83.5) 192 (74.7) 28 (22.0)
Erosion 21 (24.7) 38 (43.7) 54 (63.5) 113 (44.0) 17 (13.4)
Pain 26 (30.6) 34 (39.1) 52 (61.2) 112 (43.6) 7 (5.5)
Edema 12 (14.1) 28 (32.2) 51 (60.0) 91 (35.4) 6 (4.7)

During clinical trials, irritation generally began on day 4 and persisted for the remainder of treatment. Severity of facial irritation at the last treatment visit was slightly below baseline for the vehicle group, mild to moderate for the 1 week active treatment group, and moderate for the 2 and 4 week active treatment groups. Mean severity declined rapidly for each active group after completion of treatment and was below baseline for each group at the week 2 post-treatment follow-up visit.

Thirty-one patients (12% of those treated with Carac (fluorouracil) in the Phase 3 clinical studies) discontinued study treatment early due to facial irritation. Except for three patients, discontinuation of treatment occurred on or after day 11 of treatment.

Eye irritation adverse events, described as mild to moderate in intensity, were characterized as burning, watering, sensitivity, stinging and itching. These adverse events occurred across all treatment arms in one of the two Phase 3 studies.

Summary of All Adverse Events Reported in ≥ 1% of Patients in the Combined Active Treatment and Vehicle Groups – Pooled Phase 3 Studies

View Enlarged Table

Adverse Experiences Reported by Body System

In the Phase 3 studies, no serious adverse event was considered related to study drug. A total of five patients, three in the active treatment groups and two in the vehicle group, experienced at least one serious adverse event. Three patients died as a result of adverse event(s) considered unrelated to study drug (stomach cancer, myocardial infarction and cardiac failure).

Post-treatment clinical laboratory tests other than pregnancy tests were not performed during the Phase 3 clinical studies. Clinical laboratory tests were performed during conduct of a Phase 2 study of 104 patients and 21 patients in a Phase 1 study. No abnormal serum chemistry, hematology, or urinalysis results in these studies were considered clinically significant.

Read the Carac (fluorouracil) Side Effects Center for a complete guide to possible side effects

Learn More »

Interactions

No information provided.

This monograph has been modified to include the generic and brand name in many instances.

Warnings

The potential for a delayed hypersensitivity reaction to fluorouracil exists. Patch testing to prove hypersensitivity may be inconclusive.

Patients should discontinue therapy with Carac (fluorouracil) if symptoms of DPD enzyme deficiency develop.

Rarely, unexpected, systemic toxicity (e.g. stomatitis, diarrhea, neutropenia, and neurotoxicity) associated with parenteral administration of fluorouracil has been attributed to deficiency of dihydropyrimidine dehydrogenase “DPD” activity. One case of life threatening systemic toxicity has been reported with the topical use of 5% fluorouracil in a patient with a complete absence of DPD enzyme activity. Symptoms included severe abdominal pain, bloody diarrhea, vomiting, fever, and chills. Physical examination revealed stomatitis, erythematous skin rash, neutropenia, thrombocytopenia, inflammation of the esophagus, stomach, and small bowel. Although this case was observed with 5% fluorouracil cream, it is unknown whether patients with profound DPD enzyme deficiency would develop systemic toxicity with lower concentrations of topically applied fluorouracil.

Applications to mucous membranes should be avoided due to the possibility of local inflammation and ulceration.

Precautions

General

There is a possibility of increased absorption through ulcerated or inflamed skin.

Information for the Patient

Patients using Carac (fluorouracil) should receive the following information and instructions:

  1. This medication is to be used as directed.
  2. This medication should not be used for any disorder other than that for which it was prescribed.
  3. It is for external use only.
  4. Avoid contact with the eyes, eyelids, nostrils, and mouth.
  5. Cleanse affected area and wait 10 minutes before applying Carac (fluorouracil) .
  6. Wash hands immediately after applying Carac (fluorouracil) .
  7. Avoid prolonged exposure to sunlight or other forms of ultraviolet irradiation during treatment, as the intensity of the reaction may be increased.
  8. Most patients using Carac (fluorouracil) get skin reactions where the medicine is used. These reactions include redness, dryness, burning, pain, erosion (loss of the upper layer of skin), and swelling. Irritation at the application site may persist for two or more weeks after therapy is discontinued. Treated areas may be unsightly during and after therapy.
  9. If you develop abdominal pain, bloody diarrhea, vomiting, fever, or chills while on Carac (fluorouracil) therapy, stop the medication and contact your physician and/or pharmacist.
  10. Report any side effects to the physician and/or pharmacist.

Laboratory Tests

To rule out the presence of a frank neoplasm, a biopsy may be considered for those areas failing to respond to treatment or recurring after treatment.

Carcinogenesis, Mutagenesis and Impairment of Fertility

Adequate long-term studies in animals to evaluate carcinogenic potential have not been conducted with fluorouracil. Studies with the active ingredient of Carac, fluorouracil, have shown positive effects in in vitro and in vivo tests for mutagenicity and on impairment of fertility in in vivo animal studies.

Fluorouracil produced morphological transformation of cells in in vitro cell transformation assays. Morphological transformation was also produced in an in vitroassay by a metabolite of fluorouracil, and the transformed cells produced malignant tumors when injected into immunosuppressed syngeneic mice. Fluorouracil has been shown to exert mutagenic activity in yeast cells, Bacillus subtilis, and Drosophila assays. In addition, fluorouracil has produced chromosome damage at concentrations of 1.0 and 2.0 mcg/mL in an in vitro hamster fibroblast assay, was positive in a microwell mouse lymphoma assay, and was positive in in vivo micronucleus assays in rats and mice following intraperitoneal administration. Some patients receiving cumulative doses of 0.24 to 1.0 g of fluorouracil parenterally have shown an increase in numerical and structural chromosome aberrations in peripheral blood lymphocytes.

Fluorouracil has been shown to impair fertility after parenteral administration in rats. Fluorouracil administered at intraperitoneal doses of 125 and 250 mg/kg has been shown to induce chromosomal aberrations and changes in chromosome organization of spermatogonia in rats. In mice, single-dose intravenous and intraperitoneal injections of fluorouracil have been reported to kill differentiated spermatogonia and spermatocytes at a dose of 500 mg/kg and produce abnormalities in spermatids at 50 mg/kg.

Pediatric Use

Actinic keratosis is not a condition seen within the pediatric population, except in association with rare genetic diseases. Carac (fluorouracil) should not be used in children. The safety and effectiveness of Carac (fluorouracil) have not been established in patients less than 18 years old.

Geriatric Use

No significant differences in safety and efficacy measures were demonstrated in patients age 65 and older compared to all other patients.

Pregnancy

Teratogenic Effects: Pregnancy Category X: See CONTRAINDICATIONS.

Nursing Women

It is not known whether fluorouracil is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from fluorouracil, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

This monograph has been modified to include the generic and brand name in many instances.

OverDose

Ordinarily, topical overdosage will not cause acute problems. If Carac (fluorouracil) is accidentally ingested, induce emesis and gastric lavage. Administer symptomatic and supportive care as needed. If contact is made with the eye, flush with copious amounts of water.

ContrainDications

Fluorouracil may cause fetal harm when administered to a pregnant woman. Fluorouracil is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

No adequate and well-controlled studies have been conducted in pregnant women with either topical or parenteral forms of fluorouracil. One birth defect (ventricular septal defect) and cases of miscarriage have been reported when fluorouracil was applied to mucous membrane areas. Multiple birth defects have been reported in the fetus of a patient treated with intravenous fluorouracil.

Animal reproduction studies have not been conducted with Carac. Fluorouracil, the active ingredient, has been shown to be teratogenic in mice, rats, and hamsters when administered parenterally at doses greater than or equal to 10, 15 and 33 mg/kg/day, respectively, [4X, 11X and 20X, respectively, the Maximum Recommended Human Dose (MRHD) based on body surface area (BSA)]. Fluorouracil was administered during the period of organogenesis for each species. Embryolethal effects occurred in monkeys at parenteral doses greater than 40 mg/kg/day (65X the MRHD based on BSA) administered during the period of organogenesis.

Carac (fluorouracil) should not be used in patients with dihydropyrimidine dehydrogenase (DPD) enzyme deficiency. A large percentage of fluorouracil is catabolized by the enzyme dihydropyrimidine dehydrogenase (DPD). DPD enzyme deficiency can result in shunting of fluorouracil to the anabolic pathway, leading to cytotoxic activity and potential toxicities.

Carac (fluorouracil) is contraindicated in patients with known hypersensitivity to any of its components.

This monograph has been modified to include the generic and brand name in many instances.

Clinical Pharamacology

There is evidence that the metabolism of fluorouracil in the anabolic pathway blocks the methylation reaction of deoxyuridylic acid to thymidylic acid. In this manner, fluorouracil interferes with the synthesis of deoxyribonucleic acid (DNA) and to a lesser extent inhibits the formation of ribonucleic acid (RNA). Since DNA and RNA are essential for cell division and growth, the effect of fluorouracil may be to create a thymine deficiency that provokes unbalanced growth and death of the cell. The effects of DNA and RNA deprivation are most marked on those cells that grow more rapidly and take up fluorouracil at a more rapid rate. The contribution to efficacy or safety of individual components of the vehicle has not been established.

Pharmacokinetics

A multiple-dose, randomized, open-label, parallel study was performed in 21 patients with actinic keratoses. Twenty patients had pharmacokinetic samples collected: 10 patients treated with Carac (fluorouracil) and 10 treated with Efudex®‡‡ 5% Cream. Patients were treated for a maximum of 28 days with Carac (fluorouracil) , 1 g once daily in the morning; or Efudex® 5% Cream, 1 g twice daily, in the morning and evening. Steady-state plasma concentrations and the amounts of fluorouracil in urine resulting from the topical application of either product were measured.

Three patients who received Carac (fluorouracil) and nine patients who received Efudex® 5% Cream had measurable plasma fluorouracil levels; however, only one patient receiving Carac (fluorouracil) and six patients receiving Efudex® 5%Cream had a sufficient number of data points to calculate mean pharmacokinetic parameters.

Plasma Pharmacokinetic Summary

PK Parameter Carac
n=1
Efudex (Mean ± SD)
n=6
Cmax 0.77 ng/mL 11.49 ± 8.24 ng/ml
Tmax 1.00 hr 1.03 ± 0.028 hr
AUC (0-24) 2.80 ng•hr/ml 22.39 ± 7.89 ng.hr/ml

Five of 10 patients receiving Carac (fluorouracil) and nine of 10 patients receiving Efudex® 5% Cream had measurable urine fluorouracil levels.

Urine Pharmacokinetic Summary

PK Parameter Carac (fluorouracil) (Mean ± SD)
(Range)
n=10
Efudex (Mean ± SD)
(Range)
n=10
Cum Ae
(min-max)
2.74 ± 5.22 mcg
(0-15.02)
119.83 ± 94.80 mcg
(0-329.87)
Max excretion rate
(min-max)
0.19 ± 0.52 mcg/hr
(0-1.67)
40.27 ± 47.14 mcg/hr
(0-164.5)
† Cumulative urinary excretion

Both Carac (fluorouracil) and Efudex® 5% Cream demonstrated low measurable plasma concentrations for fluorouracil when administered under steady-state conditions. Cumulative urinary excretion of fluorouracil was low for Carac (fluorouracil) and for Efudex®, corresponding to 0.055% and 0.24% of the applied doses, respectively.

Clinical Trials

Under the experimental conditions of the topical safety studies, Carac (fluorouracil) was not observed to cause contact sensitization. However, approximately 95% of subjects in the active arms of the Phase 3 clinical studies experienced facial irritation. Irritation is likely and sensitization is unlikely based on the results of the topical safety and Phase 3 studies.

Two Phase 3 identically designed, multi-center, vehicle-controlled, double-blind studies were conducted to evaluate the clinical safety and efficacy of Carac (fluorouracil) . Patients with 5 or more actinic keratoses (AKs) on the face or anterior bald scalp were randomly allocated to active or vehicle treatment in a 2:1 ratio. Patients were randomly allocated to treatment durations of 1, 2, or 4 weeks in a 1:1:1 ratio. They applied the study cream once daily to the entire face/anterior bald scalp. Each patient's clinical response was evaluated 4 weeks after the patient's last scheduled application of study cream. No additional post-treatment follow-up efficacy or safety assessments were performed beyond 4 weeks after the last scheduled application. The following graphs show the percentage of patients in whom 100% of treated lesions cleared, and the percentage of patients in whom 75% or more of treated lesions cleared. Treatment with Carac (fluorouracil) cream for 1, 2, or 4 weeks is compared to treatment with vehicle cream. Outcomes from 1, 2, and 4 weeks of treatment with vehicle cream are pooled because duration of treatment with vehicle had no substantive effect on clearance. Results from the two Phase 3 studies are shown separately. Although all treatment regimens of Carac (fluorouracil) studied demonstrated efficacy over vehicle for the treatment of actinic keratosis, continuing treatment up to 4 weeks as tolerated results in further lesion reduction and clearing.

Percentage of Subjects with 100% Clearance

Percentage of Subjects with 100% Clearance - Illustration

Percentage of Subjects with at Least 75% Clearance

Percentage of Subjects with at Least 75% Clearance  - Illustration

Clinical efficacy and safety in the treatment of AKs on the ears and other sun-exposed areas were not evaluated in the studies.

This monograph has been modified to include the generic and brand name in many instances.

Patient Information

Carac® Cream, 0.5% (fluorouracil)
(fluorouracil cream)

Read this leaflet carefully before you start to use your medicine. Read the information you get every time you get more medicine. There may be new information about the drug. This leaflet does not take the place of talks with your doctor. If you have any questions or are not sure about something, ask your doctor or pharmacist.

What is Carac (fluorouracil) ?

Carac (fluorouracil) (Care ack) is a cream used by adults to treat skin conditions on the face and front part of the scalp called solar keratosis or actinic keratosis.

Who should not use Carac (fluorouracil) ?

Do not use Carac (fluorouracil)

  • if you are pregnant or might become pregnant. Carac (fluorouracil) may harm your unborn child.
  • if you are nursing a baby. We do not know if Carac (fluorouracil) can pass to the baby through the milk.
  • If you have dihydropyrimidine dehydrogenase (DPD) enzyme deficiency. The active ingredient in Carac, fluorouracil, can cause serious side effects in patients who are DPD enzyme deficient. If you have DPD enzyme deficiency and use medications containing fluorouracil, you may develop serious side effects such as stomach pain, bloody diarrhea, vomiting, fever, or chills.
  • If you are allergic to the ingredients in Carac (fluorouracil) . Ask your doctor or pharmacist about the inactive ingredients.
  • If under 18 years of age. Carac (fluorouracil) should not be used in children.

Tell your doctor if you are able to become pregnant. Your doctor may advise you about birth control to avoid pregnancy.

How should I use Carac (fluorouracil) ?

Use Carac (fluorouracil) once a day as instructed by your doctor. Use it only on your skin. You should use Carac (fluorouracil) for up to 4 weeks.

  1. Clean the area where you will apply Carac (fluorouracil) . Rinse well and dry the area with a towel and wait 10 minutes before applying Carac (fluorouracil) .
  2. Put Carac (fluorouracil) on your face as directed by your physician, using your fingertips. Use enough to cover the affected skin.
  3. Avoid contact with your eyes, nostrils, and mouth.
  4. Wash your hands as soon as you finish putting the Carac (fluorouracil) on your skin.
  5. A moisturizer/sunscreen may be applied 2 hours after Carac (fluorouracil) has been applied. Do not use any other skin products including creams, lotions, medications or cosmetics –unless instructed by your doctor.

What should I avoid while using Carac (fluorouracil) ?

Avoid sunlight or other ultraviolet light (such as tanning booths) as much as possible while using Carac (fluorouracil) . Sunlight may increase your side effects. When exposed to sunlight, wear a hat and use sunscreen.

Do not cover the treated skin with a dressing.

Do not breast feed or become pregnant while using Carac (fluorouracil) . If you do become pregnant, stop using Carac (fluorouracil) and tell your doctor right away.

What are the possible side effects of Carac (fluorouracil) ?

Most patients using Carac (fluorouracil) get skin reactions where the medicine is used. These reactions include redness, dryness, burning, pain, erosion (loss of the upper layer of skin), and swelling. Irritation may continue for two or more weeks after treatment is over. The treated area may become unsightly during therapy.

Some patients get eye irritation. Eye irritation might consist of burning, sensitivity, itching, stinging, and watering. If you are concerned about side effects, talk to your doctor.

A few patients have reported side effects such as stomach pain, diarrhea, vomiting, fever, or chills, possibly due to the lack of a specific enzyme, DPD, in their body. If you experience any of these symptoms, discontinue therapy immediately, and contact your doctor.

Storage information

Keep this medicine at room temperature (68-77°F/ 20-25°C). Throw away unused medicine. Keep this medicine out of the reach of children.

General advice about prescription medicines

Medicines are sometimes prescribed for conditions that are not described in patient information leaflets. Do not use it for a condition for which it was not prescribed. This medicine is for your use only. Never give it to other people. It may harm them even if their skin problem appears to be the same as yours. Do not use Carac (fluorouracil) after the expiration date on the tube.

Prescribing Information as of November 2006.

This monograph has been modified to include the generic and brand name in many instances.

Consumer Overview Uses

No Information Available!

Consumer Overview Side Effect

No Information Available!

Consumer Overview Missed Dose

No Information Available!

Patient Detailed Side Effect

Brand Names: Carac, Efudex, Efudex Occlusion Pack, Fluoroplex

Generic Name: fluorouracil topical (Pronunciation: flore oh YER a sill)

  • What is fluorouracil topical (Carac)?
  • What are the possible side effects of fluorouracil topical (Carac)?
  • What is the most important information I should know about fluorouracil topical (Carac)?
  • What should I discuss with my healthcare provider before using fluorouracil topical (Carac)?
  • How should I use fluorouracil topical (Carac)?
  • What happens if I miss a dose (Carac)?
  • What happens if I overdose (Carac)?
  • What should I avoid while using fluorouracil topical (Carac)?
  • What other drugs will affect fluorouracil topical (Carac)?
  • Where can I get more information?

What is fluorouracil topical (Carac)?

Fluorouracil interferes with the growth of skin cells. Fluorouracil works by causing the death of cells which are growing fastest, such as abnormal skin cells.

Fluorouracil topical is used to treat scaly overgrowths of skin (actinic or solar keratoses). Fluorouracil topical may also be used in the treatment of superficial basal cell carcinoma.

Fluorouracil topical may also be used for purposes other than those listed in this medication guide.

What are the possible side effects of fluorouracil topical (Carac)?

Serious side effects are not likely to occur. Stop using fluorouracil topical and seek emergency medical attention if you experience an allergic reaction (shortness of breath; closing of your throat; swelling of your lips, face, or tongue; or hives).

Fluorouracil topical may cause skin irritation, dryness, scaling or peeling (exfoliation), rash, and other local reactions. Eye irritation has also been reported. If these side effects are excessive or worsen with continued treatment, contact your doctor.

Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome. You may report side effects to FDA at 1-800-FDA-1088.

Read the Carac (fluorouracil) Side Effects Center for a complete guide to possible side effects

Learn More »

What is the most important information I should know about fluorouracil topical (Carac)?

Do not use fluorouracil topical on skin that is irritated, peeling, or infected or on open wounds. Wait until these conditions have fully healed before using fluorouracil topical.

Fluorouracil topical is in the FDA pregnancy category X. This means that it is known to harm an unborn baby. Miscarriage and birth defects have been reported when fluorouracil topical was applied to mucous membrane areas by pregnant women. Do not use fluorouracil topical if you are pregnant or planning a pregnancy. Discuss with your doctor appropriate forms of birth control before starting treatment with fluorouracil topical.

Fluorouracil topical is available in a number of strengths and forms (creams and solutions). It is very important that you use the correct form and strength. Contact your doctor or pharmacist if you have questions regarding which product to use.

Avoid exposure to sunlight or artificial UV rays (e.g., sun lamps) during and immediately following treatment with fluorouracil topical. Use a sunscreen with a minimum sun protection factor (SPF) 15 and wear protective clothing when sun exposure is unavoidable. Individuals with fair skin may require a sunscreen with a higher SPF rating.

Side Effects Centers
  • Carac
  • Efudex
  • Fluoroplex

Patient Detailed How Take

What should I discuss with my healthcare provider before using fluorouracil topical (Carac)?

Before using fluorouracil topical, tell your doctor if you:

  • have ever had an allergic reaction to another form of fluorouracil topical (Carac, Efudex, Fluoroplex) or injectable fluorouracil (Adrucil, 5-FU); or
  • have dihydropyrimidine dehydrogenase (DPD) enzyme deficiency.

You may not be able to use fluorouracil topical, or you may require a dosage adjustment or special monitoring during treatment if you have any of the conditions listed above.

Fluorouracil topical is in the FDA pregnancy category X. This means that it is known to harm an unborn baby. Miscarriage and birth defects have been reported when fluorouracil topical was applied to mucous membrane areas by pregnant women. Do not use fluorouracil topical if you are pregnant or planning a pregnancy. Discuss with your doctor appropriate forms of birth control before starting treatment with fluorouracil topical.

It is not known whether fluorouracil topical passes into breast milk. Do not use fluorouracil topical without first talking to your doctor if you are breast-feeding a baby.

The safety and effectiveness of fluorouracil topical in patients younger than 18 years of age have not been established.

How should I use fluorouracil topical (Carac)?

Use fluorouracil topical exactly as directed by your doctor. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.

Fluorouracil topical is available in a number of strengths and forms (creams and solutions). It is very important that you use the correct form and strength. Contact your doctor or pharmacist if you have questions regarding which product to use.

Clean the area where you will apply fluorouracil topical. Rinse well and dry the area with a towel and wait ten minutes before applying the medication.

Wash your hands before and immediately after applying this medication, unless it is being used to treat a hand condition.

Apply fluorouracil topical to the affected area with the finger tips or a non-metal applicator, smoothing it gently onto the affected skin. Use enough to cover the entire area with a thin film.

Fluorouracil topical should not be applied on the eyelids or in the eyes, nose, or mouth. Use caution when applying fluorouracil topical around the eyes, nose, or mouth.

Do not use fluorouracil topical on skin that is irritated, peeling, or infected or on open wounds. Wait until these conditions have fully healed before using fluorouracil topical.

Do not cover the area after applying fluorouracil topical. This could cause too much medicine to be absorbed by the body and could be harmful. If a covering is needed, ask your doctor if a porous gauze dressing may be used.

A moisturizer or sun screen may be applied 2 hours after fluorouracil topical has been applied. Do not use any other skin products including creams, lotions, medications, or cosmetics unless instructed by your doctor.

The reaction of the skin treated with fluorouracil topical may be unsightly during treatment, and sometimes, for several weeks after completion of therapy.

Store fluorouracil topical at room temperature away from moisture and heat.

Side Effects Centers
  • Carac
  • Efudex
  • Fluoroplex

Patient Detailed Avoid Taking

What happens if I miss a dose (Carac)?

Apply the missed dose as soon as you remember. However, if it is almost time for the next dose, skip the dose you missed and apply only the next regularly scheduled dose. Do not apply a double dose of this medication.

What happens if I overdose (Carac)?

An overdose of fluorouracil topical is unlikely to occur. If you do suspect an overdose, or if fluorouracil topical has been ingested, call a poison control center or an emergency room for advice.

What should I avoid while using fluorouracil topical (Carac)?

Do not use other prescription or over-the-counter skin products without first talking to your doctor during treatment with fluorouracil topical. They may interfere with the treatment or increase irritation of the skin.

Avoid exposure to sunlight or artificial UV rays (e.g., sun lamps) during and immediately following treatment with fluorouracil topical. Use a sunscreen with a minimum sun protection factor (SPF) 15 and wear protective clothing when sun exposure is unavoidable. Individuals with fair skin may require a sunscreen with a higher SPF rating.

What other drugs will affect fluorouracil topical (Carac)?

Do not use other prescription or over-the-counter skin products without first talking to your doctor during treatment with fluorouracil topical. They may interfere with treatment or increase irritation to the skin.

Drugs other than those listed here may also interact with fluorouracil topical. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines.

Where can I get more information?

Your pharmacist has additional information about fluorouracil topical written for health professionals that you may read.


Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2013 Cerner Multum, Inc. Version: 2.10. Revision date: 12/15/2010.

Your use of the content provided in this service indicates that you have read,understood and agree to the End-User License Agreement,which can be accessed by clicking on this link.

Healthwise

Side Effects Centers
  • Carac
  • Efudex
  • Fluoroplex

Rx Scoops
Featured Topics
Advertisements
Copyrights ©2014: Rx Scoops - Designed & Developed By - GOIGI